Evidence map›Paper›PMID 37333656›Full record

ArticleFrontiers in microbiology2023

Novel gold(III)-dithiocarbamate complex targeting bacterial thioredoxin reductase: antimicrobial activity, synergy, toxicity, and mechanistic insights.

Carlos Ratia, Victoria Ballén, Yaiza Gabasa, Raquel G Soengas, María Velasco-de Andrés, María José Iglesias, Qing Cheng, Francisco Lozano, Elias S J Arnér, Fernando López-Ortiz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Binding of Tetrachloroaurate(III) to Bovine or Human γ-Globulins.International journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Halogenated 3-Nitro-2Antibiotics (Basel, Switzerland) · 2025
    Article
  6. An organometallic hybrid antibiotic of metronidazole with a Gold(I) N-Heterocyclic Carbene overcomes metronidazole resistance in Clostridioides difficile.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Carlos RatiaBarcelona Institute for Global Health (ISGlobal), Universitat de Barcelona, Barcelona, Spain.
Victoria BallénBarcelona Institute for Global Health (ISGlobal), Universitat de Barcelona, Barcelona, Spain.
Yaiza GabasaBarcelona Institute for Global Health (ISGlobal), Universitat de Barcelona, Barcelona, Spain.
Raquel G SoengasÁrea de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain.
María Velasco-de AndrésAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
María José IglesiasÁrea de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain.
Qing ChengDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Francisco LozanoAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Fernando López-OrtizÁrea de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain.
Sara M SotoBarcelona Institute for Global Health (ISGlobal), Universitat de Barcelona, Barcelona, Spain.
University of Almería · ESKarolinska Institutet · SEUniversitat de Barcelona · ESBarcelona Institute for Global Health · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínic de Barcelona · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antimicrobial resistance is a pressing global concern that has led to the search for new antibacterial agents with novel targets or non-traditional approaches. Recently, organogold compounds have emerged as a promising class of antibacterial agents. In this study, we present and characterize a (C^S)-cyclometallated Au(III) dithiocarbamate complex as a potential drug candidate. Methods and results: The Au(III) complex was found to be stable in the presence of effective biological reductants, and showed potent antibacterial and antibiofilm activity against a wide range of multidrug-resistant strains, particularly gram-positive strains, and gram-negative strains when used in combination with a permeabilizing antibiotic. No resistant mutants were detected after exposing bacterial cultures to strong selective pressure, indicating that the complex may have a low propensity for resistance development. Mechanistic studies indicate that the Au(III) complex exerts its antibacterial activity through a multimodal mechanism of action. Ultrastructural membrane damage and rapid bacterial uptake suggest direct interactions with the bacterial membrane, while transcriptomic analysis identified altered pathways related to energy metabolism and membrane stability including enzymes of the TCA cycle and fatty acid biosynthesis. Enzymatic studies further revealed a strong reversible inhibition of the bacterial thioredoxin reductase. Importantly, the Au(III) complex demonstrated low cytotoxicity at therapeutic concentrations in mammalian cell lines, and showed no acute Discussion: Overall, these findings highlight the potential of the Au(III)-dithiocarbamate scaffold as a basis for developing novel antimicrobial agents, given its potent antibacterial activity, synergy, redox stability, inability to produce resistant mutants, low toxicity to mammalian cells both

Indexed as

cycloauratedithiocarbamategold(III) complexMDRMRSAsynergy

Identifiers

PMID37333656
PMCPMC10272563
OpenAlexW4379230207

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.